Abstract��OBJECTIVE To investigate the impacts of particle size and preferred orientation on relative peak intensity, number of peaks and order of peak intensity in powder X-ray diffraction (PXRD) analysis of organic and inorganic pharmaceutical crystalline materials and evaluate the phase identification methods in various pharmaceutical compendiums.METHODS The PXRD patterns of organic and inorganic materials with different particle sizes obtained by sieving or grinding were acquired and the number of diffraction peaks, peak position and intensity of diffraction peaks were compared across different samples. RESULTS Due to preferred orientation effects, the diffraction patterns of samples with different particle sizes were apparently different, including the number of peaks, relative peak intensity and the order of the peak intensity. CONCLUSION Scientists may get different CONCLUSION s from the RESULTS of same tests performed according to the related guiding principles of current Chinese Pharmacopeia and USP39, EP8.0, JP16 ���� pharmacopoeia for identifying the crystalline forms.The phase identification by PXRD method in current Chinese Pharmacopeia neglects the effects of preferred orientation on diffraction peaks and relative peak intensity. This guideline needs to be updated to better reflect the scientific observation in industry and align with other well accepted compendiums such as USP, EP and JP.
Specifications:Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances Q6A[S]. International conference on harmonization oftechnical requirements for registration of pharmaceuticals for human use, 1999 Oct. 06.
[4]
BYRN S R, PFEIFFER R, STOWELL J G. Solid-State Chemistry of Drugs[M]. 2nd ed. INDIANA: SSCI, Inc. , West Lafayette,1999.
[5]
PECHARSKY V K, ZAVALIJ P Y. Fundamentals of Powder Diffractionand Structural Characterization of Materials [M]. Springer, 2005:161.
[6]
ZHENG J L, TRASK A V. Crystal forms of azithromycin. US, 7309782B2[P]. 20071218.
[7]
LU Q H, KU M S, QIU W, et al. Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinyl- methoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof. China,101918390B[P]. 20140618.
2017, Vol. 52 
